Canada Pension Plan Investment Board Increases Stake in 10x Genomics, Inc. (NASDAQ:TXG)

Canada Pension Plan Investment Board raised its holdings in shares of 10x Genomics, Inc. (NASDAQ:TXG - Free Report) by 27.1% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 200,200 shares of the company's stock after buying an additional 42,700 shares during the period. Canada Pension Plan Investment Board owned about 0.17% of 10x Genomics worth $2,875,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Signaturefd LLC increased its stake in shares of 10x Genomics by 424.6% in the fourth quarter. Signaturefd LLC now owns 1,794 shares of the company's stock worth $26,000 after buying an additional 1,452 shares during the period. Blue Trust Inc. increased its stake in shares of 10x Genomics by 73.1% in the fourth quarter. Blue Trust Inc. now owns 3,075 shares of the company's stock worth $44,000 after buying an additional 1,299 shares during the period. Sound Income Strategies LLC increased its stake in shares of 10x Genomics by 65.2% in the fourth quarter. Sound Income Strategies LLC now owns 3,370 shares of the company's stock worth $48,000 after buying an additional 1,330 shares during the period. Mirae Asset Global Investments Co. Ltd. bought a new stake in shares of 10x Genomics in the fourth quarter worth about $52,000. Finally, SRS Capital Advisors Inc. increased its holdings in 10x Genomics by 817.4% during the 4th quarter. SRS Capital Advisors Inc. now owns 4,853 shares of the company's stock valued at $70,000 after purchasing an additional 4,324 shares during the period. 84.68% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of equities research analysts have recently weighed in on TXG shares. Citigroup cut their price objective on 10x Genomics from $20.00 to $15.00 and set a "buy" rating on the stock in a research report on Tuesday, March 4th. Morgan Stanley cut their price target on shares of 10x Genomics from $28.00 to $26.00 and set an "overweight" rating on the stock in a report on Friday, February 14th. Leerink Partners downgraded shares of 10x Genomics from an "outperform" rating to a "market perform" rating and reduced their price objective for the company from $25.00 to $12.00 in a research report on Thursday, February 13th. Barclays dropped their target price on shares of 10x Genomics from $15.00 to $12.00 and set an "overweight" rating for the company in a research report on Thursday, April 10th. Finally, UBS Group reduced their price target on shares of 10x Genomics from $20.00 to $14.00 and set a "neutral" rating on the stock in a research report on Thursday, February 13th. One research analyst has rated the stock with a sell rating, nine have assigned a hold rating and seven have given a buy rating to the company. According to data from MarketBeat.com, 10x Genomics presently has a consensus rating of "Hold" and a consensus target price of $19.79.

10x Genomics Stock Up 2.2 %

Shares of NASDAQ TXG traded up $0.18 during trading on Monday, reaching $8.48. The company had a trading volume of 3,178,655 shares, compared to its average volume of 2,266,116. The business's 50-day moving average is $9.40 and its 200 day moving average is $12.98. The stock has a market cap of $1.04 billion, a PE ratio of -5.58 and a beta of 2.01. 10x Genomics, Inc. has a 12-month low of $6.78 and a 12-month high of $29.37.

10x Genomics (NASDAQ:TXG - Get Free Report) last announced its quarterly earnings results on Wednesday, February 12th. The company reported ($0.40) earnings per share for the quarter, missing the consensus estimate of ($0.32) by ($0.08). 10x Genomics had a negative net margin of 29.90% and a negative return on equity of 25.40%. On average, analysts anticipate that 10x Genomics, Inc. will post -1.43 earnings per share for the current year.

Insider Activity at 10x Genomics

In other news, insider Benjamin J. Hindson sold 4,573 shares of the stock in a transaction on Monday, February 24th. The stock was sold at an average price of $11.07, for a total transaction of $50,623.11. Following the transaction, the insider now directly owns 335,324 shares of the company's stock, valued at $3,712,036.68. This represents a 1.35 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director Alan Mateo acquired 40,000 shares of the business's stock in a transaction that occurred on Friday, February 21st. The stock was purchased at an average cost of $11.14 per share, with a total value of $445,600.00. Following the acquisition, the director now directly owns 61,691 shares of the company's stock, valued at $687,237.74. This trade represents a 184.41 % increase in their ownership of the stock. The disclosure for this purchase can be found here. 10.03% of the stock is currently owned by insiders.

About 10x Genomics

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.